LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

LLY

752.52

+1.27%↑

JNJ

155.51

-0.4%↓

UNH

382.03

-1.48%↓

ABBV

187.81

+2.41%↑

ABT

134.51

+0.37%↑

Search

Novo Nordisk A-S

Abrir

SetorSaúde

66.5 2.58

Visão Geral

Variação de preço das ações

24h

Atual

Mín

64.76

Máximo

67.39

Indicadores-chave

By Trading Economics

Rendimento

929M

28B

Vendas

14B

86B

P/E

Médio do Setor

20.184

54.379

EPS

6.34

Rendimento de Dividendos

2.33

Margem de lucro

32.947

Funcionários

76,302

EBITDA

4.2B

40B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+36.74% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.33%

2.55%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

21B

306B

Abertura anterior

63.92

Fecho anterior

66.5

Sentimento de Notícias

By Acuity

43%

57%

179 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Novo Nordisk A-S Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de mai. de 2025, 11:29 UTC

Principais Notícias
Ganhos
Grandes Movimentos do Mercado

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

7 de mai. de 2025, 07:05 UTC

Ganhos

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

7 de mai. de 2025, 06:19 UTC

Ganhos

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

7 de mai. de 2025, 15:13 UTC

Ganhos

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7 de mai. de 2025, 13:56 UTC

Ganhos

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 de mai. de 2025, 13:45 UTC

Ganhos

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7 de mai. de 2025, 11:25 UTC

Ganhos

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7 de mai. de 2025, 11:18 UTC

Ganhos

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 de mai. de 2025, 09:55 UTC

Ganhos

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

7 de mai. de 2025, 09:36 UTC

Ganhos

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

7 de mai. de 2025, 09:04 UTC

Ganhos
Ações em Alta

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

7 de mai. de 2025, 08:10 UTC

Conversa de Mercado

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

7 de mai. de 2025, 08:08 UTC

Conversa de Mercado

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

7 de mai. de 2025, 07:11 UTC

Conversa de Mercado
Ganhos

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

7 de mai. de 2025, 05:39 UTC

Ganhos

Novo Nordisk: Sales Outlook Assumes Reduction in Patients on Compounded GLP-1 Treatments During 2H25

7 de mai. de 2025, 05:38 UTC

Ganhos

Novo Nordisk 1Q Wegovy Drug Sales Rose 83% To DKK17.36B, Consensus Saw DKK18.5B

7 de mai. de 2025, 05:37 UTC

Ganhos

Novo Nordisk 1Q Ozempic Drug Sales Rose 15% To DKK32.72B, Consensus Saw DKK32.01B

7 de mai. de 2025, 05:36 UTC

Ganhos

Novo Nordisk 1Q Gross Margin 83.5% Vs 84.8%

7 de mai. de 2025, 05:35 UTC

Ganhos

Novo Nordisk: Focused on Preventing Unlawful Compounding and Further Expanding Access in US

7 de mai. de 2025, 05:34 UTC

Ganhos

Novo Nordisk: US Sales of Branded GLP-1 Treatments Impacted By Compounded Versions

7 de mai. de 2025, 05:34 UTC

Ganhos

Novo Nordisk: Sales Outlook Reflects Lower-Than-Planned Penetration of Branded GLP-1 Treatments in US

7 de mai. de 2025, 05:33 UTC

Ganhos

Novo Nordisk: Had Seen 2025 Op Profit Growth of 19%-27% in Constant Currency

7 de mai. de 2025, 05:33 UTC

Ganhos

Novo Nordisk: Had Seen 2025 Sales Growth of 16%-24% in Constant Currency

7 de mai. de 2025, 05:33 UTC

Ganhos

Novo Nordisk Now Sees 2025 Op Profit Growth of 16%-24% in Constant Currency

7 de mai. de 2025, 05:32 UTC

Ganhos

Novo Nordisk Now Sees 2025 Sales Growth of 13%-21% in Constant Currency

7 de mai. de 2025, 05:31 UTC

Ganhos

Novo Nordisk: Analysts Saw 1Q Net Profit At DKK28.08B

7 de mai. de 2025, 05:31 UTC

Ganhos

Novo Nordisk 1Q Net Pft DKK29.03B

7 de mai. de 2025, 05:31 UTC

Ganhos

Novo Nordisk 1Q Oper Pft DKK38.79B

7 de mai. de 2025, 05:31 UTC

Ganhos

Novo Nordisk: Analysts Saw 1Q Sales at DKK77.98B

7 de mai. de 2025, 05:31 UTC

Ganhos

Novo Nordisk 1Q Sales DKK78.09B

Comparação entre Pares

Variação de preço

Novo Nordisk A-S Previsão

Preço-alvo

By TipRanks

36.74% parte superior

Previsão para 12 meses

Média 92.37 USD  36.74%

Máximo 138.226 USD

Mínimo 61 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Novo Nordisk A-S - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

9 ratings

3

Comprar

5

Manter

1

Vender

Pontuação Técnica

By Trading Central

62.63 / 69.23Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

179 / 382 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.